Table 7.
Anticoagulation in case 2.
| Prophylaxis of thromboembolic events (Q31) | |||
| 1 | IV heparin initially | 35/67 | 52.2% |
| 2 | Acetyl salicylic acid (ASA) | 20/67 | 29.9% |
| 3 | Combination of ASA and clopidogrel | 4/67 | 6.0% |
| 4 | Warfarin | 3/67 | 4.5% |
| - | Clopidogrel alone or direct oral anticoagulants (DOAC); | 0 | 0 |
| Post-acute phase thrombosis prophylaxis (Q32) | |||
| 1 | ASA | 35/66 | 53.0% |
| 2 | Subcutaneous heparin | 12/66 | 18.2% |
| 3 | None | 8/66 | 12.1% |
| 4 | Combination of ASA and clopidogrel | 6/66 | 9.1% |
| 5 | Warfarin | 5/66 | 7.6% |
| 6 | Clopidogrel | 3/66 | 4.6% |
| 7 | DOACs | 3/66 | 4.6% |
| Duration of thrombosis prophylaxis (Q35) | |||
| 3 months | 7/63 | 11.1% | |
| 6 months | 11/63 | 17.5% | |
| 12 months | 13/63 | 20.6% | |
| 18 months | 2/63 | 12.7% | |
| 24 months | 8/63 | 18.6% | |
| 36 months | 4/63 | 6.4% | |
| None | 5/63 | 7.9% | |